MEDI5752: First-in-human trial of a novel PD-1 and CTLA-4 bispecific checkpoint inhibitor

Kidney Cancer Conference Highlights from ASCO 2022Подробнее

Dr. Pecora on the Significant Results of CTLA-4 and PD-1 Combination in Multiple MyelomaПодробнее

PD1/ CTLA4 : Upfront or sequentially?Подробнее

Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibodyПодробнее

Cancer Immunotherapy - PD-1 and PD-L1Подробнее

MEDI5752: Novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumorsПодробнее

Two Main Pathways Involved in Immunotherapy PD 1 and CTLA4Подробнее

Future research directions for the novel PD-1 and CTLA-4 bispecific checkpoint inhibitor, MEDI5752Подробнее

T-DM1 Plus Pertuzumab in the MARIANNE TrialПодробнее

Bispecifics Part I: Immune System and Immunotherapy BasicsПодробнее

Utilizing Pathologic Complete Response in Breast Cancer TrialsПодробнее

Next steps in MCC: new targets and tacking PD-1 resistanceПодробнее

The basic biology of PD-1/PD-L1Подробнее

Immunology Comprehensive Revision (Inhibition -CTLA4 & PD1) Lecture 9Подробнее

15 LiverCancer (Medical IP) SW2Подробнее

PD-1 blockade after progression on bispecific CAR-T therapy in R/R B-cell malignanciesПодробнее